Alnylam Pharmaceuticals, Inc. Stock price

Equities

ALNY

US02043Q1076

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
149.4 USD -3.20% Intraday chart for Alnylam Pharmaceuticals, Inc. +1.93% -21.92%
Sales 2024 * 1.84B Sales 2025 * 2.26B Capitalization 18.82B
Net income 2024 * -524M Net income 2025 * -245M EV / Sales 2024 * 10.1 x
Net cash position 2024 * 191M Net cash position 2025 * 563M EV / Sales 2025 * 8.07 x
P/E ratio 2024 *
-35.8 x
P/E ratio 2025 *
-85.4 x
Employees 2,100
Yield 2024 *
-
Yield 2025 *
-
Free-Float 99.6%
More Fundamentals * Assessed data
Dynamic Chart
Transcript : Alnylam Pharmaceuticals, Inc. Presents at Canaccord Genuity ?Genetic Medicine for Generalists?, Mar-25-2024 01:00 PM
Transcript : Alnylam Pharmaceuticals, Inc. Presents at Stifel Virtual 2024 CNS Day, Mar-20-2024 10:00 AM
Transcript : Alnylam Pharmaceuticals, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 10:15 AM
Alnylam Pharmaceuticals Says Phase 2 Study of Hypertension Drug Zilebesiran Meets Primary Endpoint MT
Transcript : Alnylam Pharmaceuticals, Inc. Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-05-2024 09:10 AM
Alnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran Is Added to Standard of Care Antihypertensives CI
Alnylam Pharmaceuticals Insider Sold Shares Worth $4,540,071, According to a Recent SEC Filing MT
Alnylam Pharmaceuticals Insider Sold Shares Worth $455,357, According to a Recent SEC Filing MT
How long will this bullish phase last? Our Logo
ANALYST RECOMMENDATIONS : AbbVie, Doordash, Eli Lilly, Moderna, Hiscox... Our Logo
ANALYST RECOMMENDATIONS : Airbnb, Conagra Brands, Berkshire Hathaway, Meta Platforms, Unilever.... Our Logo
North American Morning Briefing : Earnings Back in -2- DJ
Chardan Cuts Price Target on Alnylam Pharmaceuticals to $225 From $250, Expects Topline Results in Mid-2024, Maintains Buy Rating MT
Goldman Sachs Downgrades Alnylam Pharmaceuticals to Neutral From Buy, Cuts Price Target to $173 From $230 MT
ANALYST RECOMMENDATIONS : Coinbase, Fortinet, Nike, Chipotle, Nvidia... Our Logo
More news
1 day-3.20%
1 week+1.93%
Current month-1.09%
1 month-3.72%
3 months-23.64%
6 months-14.12%
Current year-21.92%
More quotes
1 week
146.43
Extreme 146.4301
155.28
1 month
143.66
Extreme 143.66
155.91
Current year
143.52
Extreme 143.52
199.38
1 year
143.52
Extreme 143.52
218.88
3 years
117.58
Extreme 117.58
242.97
5 years
65.81
Extreme 65.81
242.97
10 years
31.38
Extreme 31.38
242.97
More quotes
Managers TitleAgeSince
Chief Executive Officer 61 16-09-18
Director of Finance/CFO 56 19-08-12
Compliance Officer - 22-09-20
Members of the board TitleAgeSince
Director/Board Member 70 15-12-17
Director/Board Member 72 22-08-21
Director/Board Member 68 19-01-09
More insiders
Date Price Change Volume
24-03-28 149.4 -3.20% 666,592
24-03-27 154.4 +1.59% 463,043
24-03-26 152 -0.07% 532,485
24-03-25 152.1 +3.79% 799,298
24-03-22 146.5 -0.08% 834,175

Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT

More quotes
Alnylam Pharmaceuticals, Inc. is a clinical-stage company. The Company is engaged in developing mRNA cell therapies for the treatment of autoimmune diseases. The Company’s lead product candidate, Descartes-08, is an autologous mRNA CAR-T directed against the B cell maturation antigen (BCMA). Descartes-08 targets BCMA, which exists on the surface of long-lived plasma cells and plasmacytoid dendritic cells. Descartes-08 is in Phase IIb clinical development for patients with generalized myasthenia gravis (MG). Its other product candidate includes Descartes-15 and Descartes-33. Descartes-15 is a next-generation, autologous anti-BCMA mRNA CAR-T. Using its proprietary technology and manufacturing platform, it designed Descartes-15 to be more resistant than Descartes-08 to recycling of the CAR upon multiple antigen exposures. It is developing Descartes-33 to deliver a combination of therapeutic proteins that target key drivers in the pathogenesis of autoimmunity.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
149.4 USD
Average target price
220.8 USD
Spread / Average Target
+47.71%
Consensus
  1. Stock
  2. Equities
  3. Stock Alnylam Pharmaceuticals, Inc. - Nasdaq